Kingdon Capital Management’s Flexion Therapeutics, Inc. FLXN Stock Holding History

Kingdon Capital Management’s Portfolio FLXN Stock Details FLXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100,000	Closed	-$1.87M	–	109
2018 Q3	$1.87M	Buy	+100,000	New	+$2.3M	0.13%	96
2018 Q2	–	Sell	-103,000	Closed	-$2.31M	–	145
2018 Q1	$2.31M	Buy	+103,000	New	+$2.51M	0.18%	92
2017 Q4	–	Sell	-150,000	Closed	-$3.63M	–	153
2017 Q3	$3.63M	Buy	+150,000	New	+$3.53M	0.24%	82
2017 Q2	–	Sell	-55,500	Closed	-$1.49M	–	146
2017 Q1	$1.49M	Buy	+55,500	New	+$1.13M	0.08%	97

Other funds holding FLXN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Kingdon Capital Management's FLXN Position: Q3 2021 in Review

Kingdon Capital Management sold out of Flexion Therapeutics, Inc. (FLXN) in Q3 2021, closing a stake of 893,580 shares — an estimated $7.35M sold.

Kingdon Capital Management first reported a position in FLXN in Q1 2014 and held it in 30 quarters. The position peaked at $29.4M in Q1 2017. 145 funds tracked by Wall St. Rank hold FLXN as of Q3 2021.

Kingdon Capital Management reported no remaining Flexion Therapeutics, Inc. position as of Q3 2021 after selling out during the quarter.
Kingdon Capital Management sold 893,580 Flexion Therapeutics, Inc. shares in Q3 2021, an estimated $7.35M.
Kingdon Capital Management first reported a position in Flexion Therapeutics, Inc. in Q1 2014 and held it in 30 quarters.
Kingdon Capital Management's Flexion Therapeutics, Inc. position peaked at $29.4M in Q1 2017.
145 funds tracked by Wall St. Rank held Flexion Therapeutics, Inc. as of Q3 2021.

Based on Kingdon Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.